Galapagos NV (GLPGF) — SEC Filings
Galapagos NV (GLPGF) — 50 SEC filings. Latest: 6-K (Dec 18, 2025). Includes 45 6-K, 2 SC 13D/A, 1 20-F.
View Galapagos NV on SEC EDGAR
Overview
Galapagos NV (GLPGF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 8, 2025: On December 8, 2025, Galapagos NV filed a Form 6-K to incorporate by reference a press release issued on the same date. This filing is also incorporated into several of the company's existing registration statements on Form S-8.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 49 neutral. The dominant filing sentiment for Galapagos NV is neutral.
Filing Type Overview
Galapagos NV (GLPGF) has filed 45 6-K, 1 20-F, 1 SC 13G/A, 2 SC 13D/A, 1 SC 13D with the SEC between May 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of GLPGF's 47 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 41 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Henry Gosebruch
- Aaron Cox
- Jérôme Contamine
- Omotayo Fasan, M.D.
- Pim Mutsaers, M.D.
- Dr. Paul Stoffels
- Thad Huston
- Marie José Kersten, MD
- Jeevan Shetty, MD
- Oleg Nodelman
- Richard M. Brand
- dr. Paul Stoffels
- Erica L. Hogan
- Mr. Thad Huston
- Adrian Rawcliffe
Top Tags
press-release (32) · registration-statement (18) · sec-filing (14) · filing (13) · filing-update (9) · foreign-private-issuer (5) · regulatory-filing (4) · biotech (4) · 6-K (3) · regulatory-update (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-37384 | Identifies the company's filing with the SEC. |
| Press Release Date | 20241207 | Date the press release was issued, which is incorporated by reference. |
| Filing Date | 20241209 | Date the Form 6-K was filed with the SEC. |
| Upfront Acquisition Payment | $150 million | Cash consideration for Verseau Therapeutics |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Galapagos NV (GLPGF)?
Galapagos NV has 50 recent SEC filings from May 2024 to Dec 2025, including 45 6-K, 2 SC 13D/A, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GLPGF filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 49 neutral. The dominant sentiment is neutral.
Where can I find Galapagos NV SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Galapagos NV (GLPGF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Galapagos NV?
Financial highlights for Galapagos NV are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for GLPGF?
Investment thesis data for GLPGF will be available once enriched filings are processed.
Who are the key executives at Galapagos NV?
Key executives identified across Galapagos NV's filings include Henry Gosebruch, Aaron Cox, Jérôme Contamine, Omotayo Fasan, M.D., Pim Mutsaers, M.D. and 10 others.
What are the main risk factors for Galapagos NV stock?
Of GLPGF's 47 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 41 low-risk.
What are recent predictions and forward guidance from Galapagos NV?
Forward guidance and predictions for Galapagos NV are extracted from SEC filings as they are enriched.